•
Sep 30, 2021
AcelRx Q3 2021 Earnings Report
AcelRx expanded its pipeline with Niyad™ and reported Q3 2021 financial results.
Key Takeaways
AcelRx Pharmaceuticals reported Q3 2021 total revenues of $1.9 million. The company had $48.7 million in cash and short-term investments as of September 30, 2021. AcelRx also announced the acquisition of Lowell Therapeutics, Inc. to expand its pipeline.
AcelRx to acquire Lowell Therapeutics to expand its pipeline with Niyad™.
DSUVIA® achieved 646 formulary approvals as of October 31, 2021, exceeding the year-end goal of 615 approvals.
AcelRx reports $1.9M total revenues in Q3 2021.
AcelRx had $48.7 million of cash and short-term investments as of September 30, 2021.
AcelRx
AcelRx
Forward Guidance
AcelRx expects continued growth driven by DSUVIA in plastic surgery and cosmetic procedures, and anticipates filing NDAs for two in-licensed pre-filled syringe products in 2022.
Positive Outlook
- Acquisition of Lowell will provide a late-stage asset with Breakthrough Device Designation status from the FDA.
- Anticipates potential to fulfill an unmet need for regional anticoagulation of the dialysis circuit.
- Pipeline expansion comes as DSUVIA gains traction in plastic surgery and cosmetic procedure specialties.
- Expects these two specialties to be the foundation for further DSUVIA growth.
- Plans to file New Drug Applications for two innovative pre-filled syringe product candidates in 2022.
Challenges Ahead
- Risk that the proposed acquisition may not be completed in a timely manner or at all.
- Failure to satisfy the conditions to the consummation of the proposed acquisition.
- Potential disruption to the current plans and operations of the companies.
- Risk of diverting AcelRx management’s attention from ongoing business operations.
- Unexpected variations in market growth and demand for AcelRx’s and Lowell’s products and technologies.